STERIS plc 8-K

What Happened STERIS plc announced that long-serving director Richard C. Breeden notified the Company on May 1, 2026 that he will not stand for reelection at the Company's 2026 Annual General Meeting, ending 18 years of service. On May 5, 2026 the Board increased from nine to ten members and appointed Pierre Boulud (age 54) as a director, effective that date. The Company issued a press release on May 7, 2026 announcing the appointment.

Key Details

• Richard C. Breeden informed the Company on May 1, 2026 that he will not seek reelection; his departure is not due to any disagreement with the Company.
• Board size was increased from nine to ten members and Pierre Boulud was appointed effective May 5, 2026.
• Mr. Boulud is CEO of bioMérieux since June 2023; he joined bioMérieux in 2016 and was COO from 2020–2023; prior roles include senior positions at Ipsen (2002–2016).
• Mr. Boulud will receive a prorated fee of $76,989 for the remainder of the Board’s 2025–26 term, payable in career restricted stock units under the Company’s Non-Employee Director Compensation Program, and will be eligible for the same Board indemnification program as other directors.

Why It Matters Board composition changes are material governance events that can affect oversight and strategic direction. This filing informs investors of a planned director departure and the addition of an experienced life‑sciences executive with a background in diagnostics and pharmaceutical commercial operations. The appointment is accompanied by standard compensation and indemnification arrangements disclosed in the 8-K.